Trastuzumab and paclitaxel infusion sequence

Trastuzumab (Trastuzumab) is indicated for the adjuvant treatment of node-positive or -negative breast cancer that overexpresses HER2 as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and paclitaxel or docetaxel, if combined with For paclitaxel, docetaxel, or docetaxel/carboplatin combination, during the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin) of chemotherapy, the initial dose is 4 mg/kg as an intravenous infusion over 90 minutes, followed by weekly infusions of 2 mg/kg over 30 minutes. One week after the last weekly dose of trastuzumab, 6 mg/kg of trastuzumab is administered as an intravenous infusion over 30 to 90 minutes every three weeks.